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ABSTRACT 
Background: Elevated serum gamma-glutamyltransferase (GGT) activity has been linked with an 
increased risk of chronic kidney disease (CKD) in Asian populations. We aimed to assess the prospective 
association of serum GGT with risk of CKD in a Caucasian population.  
Materials and methods: We related GGT activity to the incidence of CKD in 2,338 men aged 42-61 years 
of the Kuopio Ischemic Heart Disease study with normal kidney function at baseline. Repeat 
measurements of GGT were used to correct for within-person variability.  
Results: During a median follow-up of 25.6 years, 221 men developed new-onset CKD. The age-adjusted 
regression dilution ratio of loge GGT was 0.70 (95% CI: 0.64-0.75). Gamma-glutamyltransferase was log-
linearly associated with risk of CKD in age-adjusted analysis. In Cox regression analysis adjusted for age, 
the hazard ratio (95% CIs) for CKD per standard deviation increase in loge baseline GGT was 1.25 (1.09-
1.43) which was attenuated to 1.01 (0.86-1.19) on further adjustment for several confounders.  
Conclusion: Contrary to previous evidence of an independent association between elevated GGT and 
increased risk of CKD in Asian populations, initial evidence of an association between GGT and CKD in 
Caucasian men was confounded by body mass index, lifestyle factors, and lipids.  
 
Keywords: Chronic kidney disease; cohort study; gamma-glutamyltransferase; risk factor 
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1. Introduction 
The prevalence of chronic kidney disease (CKD) is estimated to be about 8-16% worldwide [1]. 
Common complications of CKD include anaemia, mineral and bone disorders, cognitive decline, end-
stage renal disease, and eventually death [1]. In 2010, CKD was ranked 18th in the list of causes of the 
total number of global deaths, with an annual death rate of 16.3 per 100,000 [2]. Chronic kidney disease is 
a global public health problem and its burden is increasing worldwide. Diabetes, hypertension, and 
obesity are established risk factors for CKD [1]. Other known factors involved in its pathogenesis include 
glomerulonephritis, infectious diseases, environmental pollution, abuse of analgesics, pesticides, and 
herbal medications [3]. Though these leading factors explain a large proportion of the risk of CKD, its 
pathogenesis is still not fully established as several unknown factors appear to be involved. It is therefore 
of relevance to evaluate other putative risk factors that may aid our understanding of CKD development, 
have predictive or causal relevance, and which will guide the development of preventive strategies. 
Gamma-glutamyltransferase (GGT), a known index of liver injury and commonly used as a marker for 
excessive alcohol consumption [4], has been consistently shown to be positively related with the future 
risk of several chronic disease outcomes in large-scale observational cohorts [5]. Emerging evidence also 
suggests that GGT might also be related to the risk of CKD, however, the evidence is limited and 
uncertain. Targher and colleagues using data from the US National Health and Nutrition Examination 
Survey, found a strong and independent association between increased serum GGT and CKD [6]; 
however, the temporal nature of this relationship could not be established because of the cross-sectional 
nature of their study design. Ryu and colleagues in the first prospective evaluation of GGT and CKD, 
employed a cohort of 10,337 Korean male workers with normal kidney function at baseline, and 
demonstrated increased GGT activity to be significantly associated with an increased risk of future CKD 
in a nonlinear fashion [7]. The most recent prospective cohort study conducted in urban Han Chinese also 
showed a positive relationship between GGT and CKD incidence [8]. The prospective relationship 
between GGT and CKD among general Caucasian populations has not been previously investigated. 
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Furthermore, the long-term relevance of GGT to the risk of CKD is not known. Due to measurement 
errors in assays, lifestyle changes, ageing, and chronic disease, analysis using only baseline measurements 
of an exposure could underestimate the true strength of any aetiological association between the exposure 
and disease outcome (i.e. “regression dilution bias”[9]). Given that recent evidence indicates that GGT 
exhibits high within-person variability[10], previous studies may have under-estimated the association 
between GGT and CKD. In this context, we sought to evaluate in detail, the nature and magnitude of the 
prospective association of GGT with risk of CKD, using a population-based cohort of 2,338 Caucasian 
men from eastern Finland with apparently normal renal function at baseline. Serial measurements of GGT 
performed at 4 and 11 years after baseline in a subsample of study participants enabled quantification of 
within-person variability in GGT activity. 
 
2. Materials and methods 
This report was conducted according to STROBE (STrengthening the Reporting of OBservational 
studies in Epidemiology) guidelines for reporting observational studies in epidemiology (Supplementary 
material 1).  
 
2.1. Study design and participants 
The present study is based on participants from the Kuopio Ischemic Heart Disease (KIHD) 
prospective cohort study, which was set up to investigate risk factors for cardiovascular disease (CVD) 
and other chronic disease outcomes. Details of study design and recruitment methods have been described 
in previous reports [11, 12]. Participants of the KIHD study constituted a representative sample of men 
aged 42-61 years who were living in the city of Kuopio and its surrounding rural communities in eastern 
Finland during the period of baseline examinations; which were conducted between March 1984 and 
December 1989. Of 3,433 potentially eligible and randomly selected men; 3,235 were found to be 
eligible, and of this number, 2,682 (78%) volunteered to participate; 186 provided no response to the 
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invitation and 367 declined to give informed consent. For the present analyses, we excluded participants 
with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 at baseline (n=56). The final 
dataset analysed comprised of 2,338 men who had complete information on GGT, relevant risk factors 
and markers, and CKD outcomes. The Research Ethics Committee of the University of Eastern Finland 
approved all study procedures which was conducted according to the Declaration of Helsinki. Each 
participant provided written informed consent.  
 
2.2. Assessment of risk markers 
The methods for the collection of blood specimens and measurements of lipids and biochemical 
analytes have been described previously [13]. In brief, participants were instructed to fast overnight, 
abstain from alcohol consumption for at least 3 days, and to keep away from smoking for at least 12 hours 
prior to the assessments. The blood samples were taken from study participants in the morning and serum 
samples were stored frozen at -80 °C before analyses. The kinetic method (Thermo Fisher Scientific, 
Vantaa, Finland) was used to measure GGT activity, with repeat measurements performed in a random 
subset of participants at 4 years and 11 years after the baseline measurements, as described in previous 
reports[10, 14, 15]. Serum C-reactive protein (CRP) was assessed with an immunometric assay (Immulite 
High Sensitivity C-Reactive Protein Assay; DPC, Los Angeles, CA, USA). The glucose dehydrogenase 
method (Merck, Darmstadt, Germany) was used to measure fasting plasma glucose (FPG). Participants 
completed self-administered health and lifestyle questionnaire for the assessment of age, smoking, alcohol 
consumption, socio-economic status (SES), baseline diseases, and medical history[13]. Energy 
expenditure of physical activity was assessed using the validated KIHD 12-month leisure-time physical 
activity questionnaire [16, 17]. Estimated glomerular filtration rate was estimated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation[18] using the formula: 
eGFR = 141 x (creatinine in mg/dl / 0.9)-1.209 x 0.993Age 
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2.3. Ascertainment of incident chronic kidney disease 
In the KIHD study, participants are under continuous surveillance for the development of new 
outcomes including CKD cases. All incident CKD cases that occurred from study entry to 2014 were 
included and no losses to follow-up were recorded. Chronic kidney disease outcomes were collected from 
the National Hospital Discharge Register data by computer linkage and a comprehensive review of 
available hospital records, wards of health centres, health practitioner questionnaires, and medico-legal 
reports. Chronic kidney disease was defined as kidney damage or glomerular filtration rate lower than 60 
mL/min per 1.73 m2 for 3 months or longer. 
 
2.4. Statistical analyses 
Prospective cohort analyses All skewed variables (GGT, CRP, and triglycerides) underwent log 
transformation to approximate normal distributions. Baseline characteristics were presented as means 
(SD) for continuous variables and percentages for categorical variables. Cox proportional hazard 
regression models were used to conduct time-to-event analyses after confirming assumptions of 
proportionality of hazards using Schoenfeld residuals [19]. We quantified and corrected for within-
person variability in values of GGT using adjusted regression dilution ratios (RDRs) which were 
calculated by regressing available repeat GGT measurements on baseline values [20], as described in 
detail previously. To assess the shape of the relationship between GGT and CKD risk, hazard ratios (HRs) 
and confidence intervals (CIs) were calculated within quartiles of baseline GGT values using floating 
absolute risks, and these were plotted against mean values within each GGT quartile. This was to allow 
for comparisons across the groups irrespective of the arbitrarily chosen reference category (bottom 
quartile). As the association showed a linear shape in age-adjusted analysis with a relatively flat risk of 
CKD in multivariate analysis, GGT was modelled continuously [per 1 standard deviation (SD) increase] 
and as categories (quartiles) defined according to its baseline distribution. The HRs were adjusted 
progressively for (i) age; (ii) plus body mass index (BMI), systolic blood pressure (SBP), history of 
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hypertension, prevalent coronary heart disease (CHD), smoking status, history of diabetes, total 
cholesterol, high-density lipoprotein cholesterol (HDL-C), alcohol consumption, and eGFR; and (iii) plus 
total energy intake, SES, physical activity, and CRP. We performed subgroup analyses using interaction 
tests to assess statistical evidence of any differences in hazards across categories of pre-specified 
individual level characteristics. All statistical analyses were conducted using Stata version 14 (Stata Corp, 
College Station, Texas). 
 
3. Results 
3.1. Baseline characteristics  
Baseline characteristics of the 2,338 participants included in the present analysis are summarised in 
Table 1. The mean age of study participants was 53 (SD, 5) years. Median (interquartile range) GGT 
value was 20 (15-33) U/L and the mean (SD) of loge GGT was 3.13 (0.65) U/L. Except for alcohol 
consumption, BMI, blood pressure, glucose, and CRP, baseline characteristics were generally similar 
across quartiles of serum GGT. Levels of alcohol consumption, BMI, blood pressure, fasting glucose, and 
CRP were higher in participants in the top quartile of GGT values. 
 
3.2. Correction for within-person variability in GGT  
In a random sample of 711 participants, serial measurements of GGT were taken 4 and 11 years after 
the baseline measurements, which yielded a total of 1,422 repeat measurements of GGT. Overall, the age-
adjusted RDR of loge GGT was 0.70 (95% CI: 0.64 to 0.75), which suggests that the association of GGT 
with CKD risk using baseline measurements of GGT could under-estimate the risk by [(1/0.70)-1]*100 = 
43%.  
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3.3. Gamma-glutamyltransferase and risk of chronic kidney disease 
During a median follow-up of 25.6 (interquartile range, 17.6-27.8) years, 221 CKD cases (annual rate 
4.29/1,000 person-years at risk; 95% CI: 3.76 to 4.89) were recorded. Cumulative hazard curves did not 
show a significant greater risk of new-onset CKD among males in the top quartile of GGT values 
compared to those in the bottom quartile (P = 0.187 for log-rank test; Figure 1). In age-adjusted analysis, 
a log-linear association was observed between GGT and risk of CKD, which became relatively flat on 
further adjustment for established risk factors (BMI, SBP, history of hypertension, prevalent CHD, 
smoking status, history of diabetes, total cholesterol, HDL-C, alcohol consumption, and eGFR 
(Supplementary material 2). The age-adjusted HR for CKD per 1 SD increase in GGT was 1.25 (95% 
CI: 1.09 to 1.43), which was attenuated to 1.04 (95% CI: 0.89 to 1.22) on further adjustment for 
established risk factors. The association remained absent on additional adjustment for total energy intake, 
SES, physical activity, and C-reactive protein 1.01 (95% CI: 0.86 to 1.19). Alternatively, comparing the 
top versus bottom quartiles of GGT values, the corresponding adjusted HRs were 1.59 (95% CI: 1.11 to 
2.29), 0.97 (95% CI: 0.64 to 1.47), and 0.92 (95% CI: 0.60 to 1.40) respectively (Table 2). The 
corresponding adjusted HRs per 1 SD change in usual loge GGT values were 1.37 (95% CI: 1.12 to 1.66), 
1.06 (95% CI: 0.84 to 1.32), and 1.02 (95% CI: 0.81 to 1.29) respectively (Table 2). There was no 
statistical significant evidence of effect modification by levels or categories of several clinically relevant 
characteristics and other risk markers (P for interaction ≥ 0.10 for each; Figure 2).  
 
4. Discussion 
In this large-scale population-based study of middle-aged Finnish men with apparently normal kidney 
function at baseline, we observed a log-linear association between GGT and risk of CKD disease in age-
adjusted analysis; however, the association was less robust on further adjustment for body mass index, 
blood pressure, lifestyle factors, history of diabetes, and serum lipids. The statistically non-significant 
association remained generally consistent across several clinically relevant subgroups.  
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There are limited published data on the association of GGT with CKD risk. Though a previous cross-
sectional analysis has shown GGT to be associated with albuminuria in a Chinese population;[21] to our 
knowledge, only two large-scale prospective studies conducted among Asian populations have reported 
on the associations between GGT and risk of CKD to date [7, 8] (Supplementary Material 3). Whiles 
Ryu et al. in their analysis of men without a prevalent history of hypertension or diabetes, demonstrated a 
nonlinear relationship to the association between GGT and CKD risk [7]; the findings by Shen et al. 
suggested a linear shape to the relationship, but the association was only statistically significant for men 
[8].  
Limited evidence suggests an independent association between GGT and risk of CKD and a number of 
potential mechanisms have been hypothesized to underlie the association. Ryu and colleagues speculated 
that alcohol consumption, liver disease, obesity, insulin resistance, and low-grade inflammation could 
underlie the association [7]. However, the authors suggested that it was unlikely that these were the main 
mechanisms underlying the association, as those variables were carefully accounted for in their fully-
adjusted multivariate analyses. Given that GGT has pro-oxidant properties [22] and is a source of reactive 
oxygen species (ROS), it was further suggested GGT might contribute to the pathogenesis of CKD via 
mechanisms related to oxidative stress [22]. Renal ROS has been reported to cause vasoconstriction of 
renal vasculature, which leads to sodium retention and subsequently renal damage [23, 24]. In a recent 
review of the link between non-alcoholic fatty liver disease (NAFLD) and CKD, the authors postulated 
that the origins for this relationship were via pathways such as atherogenic dyslipidemia, dysglycemia, 
and the release of pro-inflammatory, pro-coagulant, and pro-fibrogenic factors, which cause kidney 
damage [25]. Given the strong relationship between NAFLD and GGT activity, NAFLD may be the 
underlying pathology in the relationship between GGT and CKD. Our null findings are at odds with 
previous reports and several reasons could account for the conflicting results. First, the current study may 
not have had adequate power due to its relatively small sample size and low event rate compared with 
previous studies. Second, whiles the current study had a long follow-up duration of over 20 years, the 
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follow-up period for previous studies were shorter. Given the long-term follow-up of our cohort, the 
phenomenon of regression dilution may have underestimated the true association between GGT and CKD 
risk.[26, 27] Indeed, analysis of repeat measurements of GGT in a subsample of participants suggested 
that using baseline measurements of GGT could under-estimate the risk by about 40%. Third, there may 
be true differences, due to differences in study population characteristics such as age, race or genetic 
background. For instance, the current study was employed in middle-aged Caucasian men who were 
genetically homogenous, whiles the two previous studies were based in Asian populations who were 
younger.[7, 8] Our study adds to the growing literature on a potential role of GGT in the development of 
several chronic diseases [5, 15, 28-30]. Whether GGT may be a putative risk factor for CKD risk or a 
marker of underlying CKD in Caucasian populations, is still uncertain. The overall evidence on the 
relationship between GGT and CKD is indeed limited; therefore, further large-scale studies are warranted 
to investigate the associations and mechanistic studies are also needed to investigate the aetiopathogenic 
pathways postulated to underlie the GGT-CKD association. 
Our analysis used a large-scale population-based prospective cohort design with inclusion of men who 
were representative of the general population with apparently normal kidney function at study entry. 
There was a high response rate and follow-up was complete for all participants. Other strengths of the 
current analysis include the long follow-up period of over 20 years; comprehensive analysis with 
adjustment for a broad panel of lifestyle, socioeconomic factors, and biochemical markers which allowed 
adequate adjustment for several risk factors; assessment of the shape of the association and stratified 
analyses by several clinical relevant characteristics. Repeat measurements of GGT made within a random 
subset of individuals over time after baseline were available, enabling correction for within-person 
variability in GGT activity over the long period of follow-up. However, these were made in only a small 
sample of participants. Studies with repeat measurements of serum GGT in larger samples are still needed 
to assess its variability in greater detail. Some limitations deserve mention and these include: (i) the 
findings cannot be generalised to women and other populations; (ii) the potential for residual confounding 
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which is always a limitation for observational studies of this nature; and (iii) the relatively small number 
of CKD cases available. 
Contrary to previous evidence of an independent association between elevated GGT and increased risk 
of CKD in Asian populations, initial evidence of an association between GGT and CKD in middle-aged 
Caucasian men was confounded by body mass index, blood pressure, lifestyle factors, and lipids. Further 
research is needed to evaluate the prospective association between GGT and CKD risk, especially in 
women. 
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 Table 1 Baseline Participant Characteristics by Quartiles of Gamma-glutamyltransferase 
 
  
 
Overall (N=2,338) 
Mean (SD) or n (%) 
or median (IQR) 
 
Quartile 1 
(range 5-15 U/L) 
Mean (SD) or n (%) or 
median (IQR) 
 
Quartile 2 
(range 16-20 U/L) 
Mean (SD) or n (%) 
or median (IQR) 
 
Quartile 3 
(range 21-33 U/L) 
Mean (SD) or n (%) 
or median (IQR) 
 
Quartile 4 
(range ≥ 34 U/L) 
Mean (SD) or n (%) 
or median (IQR) 
GGT (U/L) 20 (15-33) 12 (11-14) 18 (16-19) 26 (23-29) 48 (40-71) 
      
Questionnaire/Prevalent conditions      
Age at survey (years) 53.1 (5.0) 53.2 (5.2) 53.4 (4.8) 53.3 (4.8) 52.6 (5.1) 
Alcohol consumption (g/week) 75.1 (135.5) 38.6 (69.8) 57.2 (85.4) 75.9 (171.0) 135.6 (165.7) 
Total energy intake, kJ/day 9,886 (2,589) 10,387 (2,577) 9,859 (2,594) 9,745 (2,574) 9,437 (2,521) 
Socioeconomic status 8.58 (4.23) 8.82 (4.18) 8.54 (4.27) 8.32 (4.26) 8.58 (4.23) 
History of diabetes 92 (3.9) 8 (1.2) 15 (3.1) 32 (5.3) 37 (6.7) 
Current smokers 742 (31.7) 193 (27.9) 153 (31.6) 202 (33.2) 194 (35.1) 
History of hypertension 706 (30.2) 131 (18.9) 143 (29.5) 198 (32.6) 234 (42.3) 
History of CHD 589 (25.2) 148 (21.4) 109 (22.5) 145 (23.9) 187 (33.8) 
      
Physical measurements      
BMI (kg/m2) 26.9 (3.6) 25.4 (2.9) 26.6 (3.3) 27.1 (3.3) 28.8 (3.9) 
SBP (mmHg) 134 (17) 129 (16) 134 (16) 135 (16) 139 (18) 
DBP (mmHg) 89 (11) 85 (10) 88 (10) 89 (10) 92 (11) 
Physical activity (kj/day) 1,541 (1,485) 1,462 (1,230) 1,634 (1,684) 1,554 (1,627) 1, 543 (1,426) 
      
Lipid markers      
Total cholesterol (mmol/l) 5.92 (1.10) 5.77 (1.12) 5.91 (1.09) 6.02 (1.14) 6.01 (1.01) 
HDL-C (mmol/l) 1.30 (0.30) 1.33 (0.29) 1.29 (0.29) 1.29 (0.31) 1.28 (0.31) 
Triglycerides (mmol/l) 1.10 (0.80-1.55) 0.95 (0.71-1.29) 1.06 (0.78-1.47) 1.16 (0.83-1.60) 1.33 (0.94-1.89) 
      
Metabolic, renal, and inflammatory 
markers 
     
Fasting plasma glucose (mmol/l) 5.36 (1.29) 5.13 (0.69) 5.26 (1.09) 5.35 (1.21) 5.77 (1.87) 
Serum creatinine (µmol/1) 88.3 (11.6) 87.4 (11.1) 88.7 (11.4) 88.7 (11.7) 88.7 (12.4) 
Estimated GFR (ml/min/1.73 m2) 87.8 (16.5) 88.6 (15.2) 87.0 (14.5) 87.2 (15.5) 88.2 (20.2) 
CRP (mg/l) 1.28 (0.71-2.46) 0.87 (0.54-1.69) 1.19 (0.74-2.13) 1.49 (0.79-2.69) 1.85 (1.04-3.77) 
 
 BMI, body mass index; CKD, chronic kidney disease; CRP, C-reactive protein; DBP, diastolic blood pressure; GGT, gamma-glutamyltransferase 
HDL-C, high-density lipoprotein cholesterol; SD, standard deviation; SBP, systolic blood pressure; 
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Table 2 Association of Serum GGT and Chronic Kidney Disease 
Serum GGT 
(U/L) 
Events/ 
Total 
Model 1  Model 2  Model 3  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Baseline GGT 
Per 1 SD 
increase 
221 / 2,338 1.25 (1.09 to 1.43) 0.002 1.04 (0.89 to 1.22) 0.630 1.01 (0.86 to 1.19) 0.877 
Q1 (5-15) 63 / 692 ref  ref  ref  
Q2 (16-20) 44 / 485 1.08 (0.73 to 1.59) 0.696 0.90 (0.61 to 1.34) 0.615 0.88 (0.59 to 1.31) 0.529 
Q3 (21-33) 58 / 608 1.18 (0.83 to 1.69) 0.352 0.96 (0.66 to 1.39) 0.817 0.91 (0.62 to 1.32) 0.614 
Q4 (≥ 34) 56 / 553 1.59 (1.11 to 2.28) 0.012 0.97 (0.64 to 1.47) 0.903 0.92 (0.60 to 1.40) 0.704 
Usual GGT* 
Per 1 SD 
increase 
221 / 2,338 1.37 (1.12 to 1.66) 0.002 1.06 (0.84 to 1.32) 0.630 1.02 (0.81 to 1.29) 0.877 
Q1 (5-15) 63 / 692 ref  ref  ref  
Q2 (16-20) 44 / 485 1.12 (0.64 to 1.93) 0.696 0.87 (0.49 to 1.52) 0.615 0.83 (0.47 to 1.47) 0.529 
Q3 (21-33) 58 / 608 1.27 (0.76 to 2.12) 0.352 0.94 (0.55 to 1.59) 0.817 0.87 (0.51 to 1.49) 0.614 
Q4 (≥ 34) 56 / 553 1.93 (1.15 to 3.24) 0.012 0.96 (0.53 to 1.74) 0.903 0.89 (0.49 to 1.62) 0.704 
 
CI, confidence interval; GGT, gamma-glutamyltransferase; HR, hazard ratio; ref, reference; Q, quartile; SD, standard deviation; 
*, indicates correction for within-person variability in values of GGT, that is, the extent to which an individual’s GGT 
measurements vary around a long-term average value (“usual GGT values”) 
Model 1: Adjusted for age  
Model 2: Model 1 plus body mass index, systolic blood pressure, history of hypertension, prevalent coronary heart disease, 
smoking status, history of diabetes, total cholesterol, high-density lipoprotein cholesterol, alcohol consumption, and estimated 
glomerular filtration rate 
Model 3: Model 2 plus total energy intake, socioeconomic status, physical activity, and C-reactive protein 
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Figure legends 
Figure 1. Cumulative hazard curves for chronic kidney disease by quartiles of gamma-
glutamyltransferase 
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CKD, chronic kidney disease; Q, quartile 
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Figure 2. Hazard ratios for baseline values of gamma-glutamyltransferase and chronic kidney disease risk 
by several participant level characteristics 
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Hazard ratios are adjusted for age, body mass index, systolic blood pressure, history of hypertension, 
prevalent coronary heart disease, smoking status, history of diabetes, total cholesterol, high-density 
lipoprotein cholesterol, alcohol consumption, and estimated glomerular filtration rate; CI, confidence 
interval; CHD, coronary heart disease; CKD, chronic kidney disease; GFR, glomerular filtration rate; 
GGT, gamma-glutamyltransferase; HR, hazard ratio; SD, standard deviation; *, P-value for interaction; 
cut-offs used for age, body mass index, systolic blood pressure, alcohol consumption, estimated 
glomerular filtration rate, and C-reactive protein are median values. 
 
 
 
